Eli Lilly weight loss drug reduces diabetes risk

Published



Eli Lilly’s popular weight loss drug, Zepbound, may reduce the risk of developing Type 2 diabetes by 94% in obese and overweight adults with prediabetes, according to preliminary results from a new long-term study published on Tuesday. 

Lilly announced the top-line results from its three-year-long SURMOUNT-1 clinical trial evaluating the long-term safety and efficacy of tirzepatide, the active ingredient in the company’s weight loss drug.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.